Compare BWB & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BWB | CTNM |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United States |
| Employees | 355 | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 571.1M | 550.7M |
| IPO Year | N/A | 2024 |
| Metric | BWB | CTNM |
|---|---|---|
| Price | $21.44 | $14.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $21.67 | $19.00 |
| AVG Volume (30 Days) | 175.9K | ★ 233.3K |
| Earning Date | 04-21-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.57 | N/A |
| Revenue Next Year | $12.35 | N/A |
| P/E Ratio | $12.97 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.35 | $6.23 |
| 52 Week High | $22.59 | $16.91 |
| Indicator | BWB | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 55.43 | 48.86 |
| Support Level | $20.79 | $13.23 |
| Resistance Level | $21.91 | $15.52 |
| Average True Range (ATR) | 0.60 | 1.15 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 82.32 | 37.21 |
Bridgewater Bancshares Inc is a financial holding company. Through its subsidiary, it offers various personal and commercial banking products and services such as savings accounts, certificates of deposits, money transfer services, digital wallets, credit and debit cards, safe deposit lockers, different types of loans and advances, commercial deposit accounts, treasury management, and others. The company principally focuses on catering to commercial clients, offering a suite of loan and deposit products. Geographically, it mainly operates in the Twin Cities Metropolitan Statistical Area in the United States.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.